دورية أكاديمية
Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
| العنوان: | Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer |
|---|---|
| المؤلفون: | Oosting, Linette T., Franke, Katka, Martin, Michael, Kloosterman, Wigard P., Jamieson, Jennifer A., Glenn, Laura A., de Jager, Miranda W., van Zanten, Jacoba, Allersma, Derk P., Gareb, Bahez |
| المصدر: | Oosting , L T , Franke , K , Martin , M , Kloosterman , W P , Jamieson , J A , Glenn , L A , de Jager , M W , van Zanten , J , Allersma , D P & Gareb , B 2022 , ' Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer ' , Pharmaceutics , vol. 14 , no. 7 , 1515 . https://doi.org/10.3390/pharmaceutics14071515Test |
| سنة النشر: | 2022 |
| المجموعة: | University of Groningen research database |
| مصطلحات موضوعية: | formulation, vaccine, neoantigen, peptide, Montanide ISA 51 VG, framome, immunotherapy, non-small cell lung cancer, personalized, SOMATIC MUTATIONS, MELANOMA |
| الوصف: | Stage III-IV non-small cell lung cancer (NSCLC) is a devastating disease characterized by a poor prognosis. NSCLC tumors carry genetic mutations, which can lead to the expression of altered protein sequences. Peptides originating from mutated proteins and bound to MHC molecules on the tumor cell surface are referred to as neoantigens, as they are tumor-specific and not expressed in normal cells. Due to their tumor specificity, neoantigens have a strong potential to induce an anti-tumor immune response and have been investigated for development of personalized therapeutic cancer vaccines. The current study describes the development of a clinical grade neoantigen vaccine formulation (FRAME-001) intended as immunotherapy in advanced NSCLC in combination with the immune checkpoint inhibitor pembrolizumab. The detection of aberrant tumor-specific transcripts as well as an algorithm to select immunogenic neoantigen peptides are described. Subsequently, selected neoantigen peptides were synthesized with a high throughput synthesis platform and aseptically formulated under good manufacturing practice (GMP) conditions into four aqueous peptides mixtures that each contained six neoantigen peptides. A validated stability-indicating analytical method was developed in which we considered the personalized nature of the formulation. An extensive stability study performed either at -25 degrees C or -80 degrees C showed that the formulation was stable for up to 32 weeks. The formulation was mixed with the vaccine adjuvant Montanide ISA 51 VG, which yielded the final vaccine emulsion. The stability of the vaccine emulsion was demonstrated using microscopic examination, differential light scattering, and the water-drop test. The presented data show that FRAME-001 is a feasible personalized vaccine formulation for the treatment of stage III-IV NSCLC. The presented data may give guidance in the development of novel personalized therapeutic vaccines since this formulation strategy could be used for any cancer indication. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://research.rug.nl/en/publications/fb374d3c-37d2-4e25-9b9a-6989207e4944Test |
| DOI: | 10.3390/pharmaceutics14071515 |
| الإتاحة: | https://doi.org/10.3390/pharmaceutics14071515Test https://hdl.handle.net/11370/fb374d3c-37d2-4e25-9b9a-6989207e4944Test https://research.rug.nl/en/publications/fb374d3c-37d2-4e25-9b9a-6989207e4944Test https://pure.rug.nl/ws/files/234450502/Development_of_a_Personalized_Tumor_Neoantigen_Based_Vaccine_Formulation_FRAME_001_for_Use_in_a_Phase_II_Trial_for_the_Treatment_of_Advanced_Non_Small_Cell_Lung_Cancer.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.304D6482 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/pharmaceutics14071515 |
|---|